H. Jung

J. Ahn, M. Ahn, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluating entrectinib as a treatment option for non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2020, Expert opinion on pharmacotherapy.

EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis

J. Ahn, M. Ahn, Se-Hoon Lee, 2022, Cancer research and treatment.

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non–small-cell lung carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2022, iScience.

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).

N. Girard, C. Escriu, Shin‐Yup Lee, 2021, Lung cancer.

Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group

R. Suzuki, Tongyu Lin, Y. Kwong, 2013, Journal of Hematology & Oncology.

Evaluation of MET alteration in EGFR-mutant non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor from paired biopsy: A retrospective cohort study

J. Ahn, M. Ahn, Yoon-La Choi, 2022, Precision and Future Medicine.

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer

J. Ahn, M. Ahn, Se-Hoon Lee, 2022, Cancer research and treatment.

Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma

J. Ahn, M. Ahn, Keunchil Park, 2022, Cancer medicine.

Dynamics of circulating immune cells during chemoradiotherapy in patients with non-small cell lung cancer support earlier administration of anti-PD-1/PD-L1 therapy.

J. Ahn, M. Ahn, Keunchil Park, 2022, International journal of radiation oncology, biology, physics.

High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma

M. Ahn, Keunchil Park, Y. Ko, 2014, Journal of Translational Medicine.

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

Jung-Il Lee, Y. Suh, J. Ahn, 2020, Nature Communications.

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

Jung Kyoon Choi, Manel Esteller, Myung-Ju Ahn, 2019, Nature Communications.

Clinicopathologic and Molecular Subtyping of EGFR Mutation-Response.

Keunchil Park, Jhingook Kim, H. Jung, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping

J. Ahn, M. Ahn, Keunchil Park, 2020, In Vivo.

Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.

J. Ahn, M. Ahn, Keunchil Park, 2019, Clinical lung cancer.

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

D. Nam, J. Ahn, M. Ahn, 2019, BMC Ophthalmology.

Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer

Donggeun Yoo, J. Ahn, M. Ahn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment

J. Ahn, M. Ahn, Se-Hoon Lee, 2023, Journal for ImmunoTherapy of Cancer.

High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients.

Ho Yun Lee, J. Ahn, M. Ahn, 2013, Anticancer research.

Pericentromeric satellite repeat expansions through RNA-derived DNA intermediates in cancer

B. Wittner, S. Ramaswamy, P. Park, 2015, Proceedings of the National Academy of Sciences.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

J. Ahn, M. Ahn, Keunchil Park, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series

M. Ahn, Keunchil Park, Y. Ko, 2015, Head & neck.

Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2019, Lung cancer.

Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect

Jong-Mu Sun, H. Jung, Jiyun Lee, 2020, Cancer Immunology, Immunotherapy.

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2020, Translational lung cancer research.

Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status.

J. Ahn, M. Ahn, Keunchil Park, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma.

J. Ahn, M. Ahn, Keunchil Park, 2020, European journal of cancer.

Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease

Ho Yun Lee, J. Ahn, M. Ahn, 2019, International journal of cancer.

Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of Cancer Research and Clinical Oncology.

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

J. Ahn, M. Ahn, Keunchil Park, 2020, Journal for ImmunoTherapy of Cancer.

A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test

J. Ahn, M. Ahn, Keunchil Park, 2015, Cancer Chemotherapy and Pharmacology.

Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?

Su Jin Lee, J. Ahn, M. Ahn, 2014, Cancer Chemotherapy and Pharmacology.

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.

J. Ahn, M. Ahn, Keunchil Park, 2021, European journal of cancer.

Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma

Su Jin Lee, Young Saing Kim, W. Chang, 2013, Melanoma research.

Genomic Characterization and Comparison of Multi-Regional and Pooled Tumor Biopsy Specimens

W. Park, Je-Gun Joung, J. Bae, 2016, PloS one.

Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma

H. Seol, Jung-Il Lee, D. Kong, 2022, Journal of Neuro-Oncology.

Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer.

Su Jin Lee, J. Ahn, Yeon-Hee Park, 2015, Clinical breast cancer.

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI

J. Ahn, M. Ahn, Se-Hoon Lee, 2022, Cancer research and treatment.

Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma

Kihyun Kim, C. Jung, S. Kim, 2014, BioMed research international.

Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease

Su Jin Lee, J. Ahn, M. Ahn, 2014, Cancer Chemotherapy and Pharmacology.

Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study

Jin Hyun Cho, Y. Ko, S. Kim, 2012, Annals of Hematology.

Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity

J. Ahn, M. Ahn, Keunchil Park, 2020, Nature Communications.

Changes in the Mean Corpuscular Volume after Capecitabine Treatment Are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer

Joon-Oh Park, S. Park, Jeeyun Lee, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence

J. Ahn, M. Ahn, Keunchil Park, 2020, Cancer medicine.

Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of Clinical Oncology.

Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea.

Su Jin Lee, J. Lee, J. Ahn, 2015, Breast.

Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells

J. Ahn, M. Ahn, H. Cha, 2023, Advanced science.

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?

J. Ahn, M. Ahn, Keunchil Park, 2020, Biology.

P2.14-61 Acquired Resistance to Entrectinib Associated with Activation of RAS Signaling Pathway in ROS1-Rearranged Non-Small Cell Lung Cancer

M. Ahn, Jong-Mu Sun, H. Jung, 2019, Journal of Thoracic Oncology.

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program

J. Ahn, M. Ahn, Keunchil Park, 2021, Cancer.

Phase II trial of combined durvalumab plus tremelimumab with proton therapy to boost the abscopal effect for recurrent or metastatic head and neck squamous cell carcinoma.

M. Ahn, Keunchil Park, Se-Hoon Lee, 2021 .

Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.

M. Ahn, Jeeyun Lee, S. Park, 2015, World journal of gastroenterology.

Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment

J. Ahn, M. Ahn, Keunchil Park, 2021, Cancer research and treatment.

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

M. Ahn, Keunchil Park, W. Chang, 2018, The Korean journal of internal medicine.

The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2021 .

Trends in Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020

J. Ahn, M. Ahn, Keunchil Park, 2023, JAMA network open.

Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience

Sun-Hee Kim, Mi-Ae Jang, Kihyun Kim, 2018, Annals of laboratory medicine.

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.

M. Ahn, W. Park, V. Anagnostou, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment

J. Ahn, M. Ahn, Keunchil Park, 2021, Translational lung cancer research.

Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.

J. Ahn, M. Ahn, Keunchil Park, 2020 .

Bevacizumab plus atezolizumab following progression on atezolizumab monotherapy in pretreated non-small cell lung cancer patients: An open-label, two-stage, phase II trial.

J. Ahn, M. Ahn, Keunchil Park, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification

D. Nam, Chul-Kee Park, S. Choi, 2023, Cancer medicine.

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

J. Ahn, M. Ahn, Keunchil Park, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

First-Line Alectinib vs. Brigatinib in Advanced NSCLC with ALK Rearrangement: Real-World Data.

J. Ahn, M. Ahn, Jong-Mu Sun, 2023, Cancer research and treatment : official journal of Korean Cancer Association.

Haemodynamic analysis of adult patients with moyamoya disease: CT perfusion and DSA gradings

J. Ahn, Keunchil Park, Soohyun Hwang, 2020, Stroke and vascular neurology.

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

M. Ahn, Keunchil Park, H. Jung, 2023, Cancer research and treatment.

Multimodal Treatments and Outcomes for Anaplastic Thyroid Cancer Before and After Tyrosine Kinase Inhibitor Therapy: A Real-World Experience.

M. Ahn, Keunchil Park, W. Park, 2021, European journal of endocrinology.

Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22

Keunchil Park, Y. Min, K. Lee, 2021, Translational Lung Cancer Research.

Pericentromeric satellite repeat expansions through RNA-derived DNA intermediates in cancer

Ben S. Wittner, S. Ramaswamy, P. Park, 2015, Proceedings of the National Academy of Sciences.

MA21.10 Phase II Study of 160mg of Osimertinib in EGFR T790M Positive NSCLC with Brain or Leptomeningeal Metastases Who Progressed on Prior EGFR TKI

Jong-Mu Sun, K. Park, J. O. Park, 2019, Journal of Thoracic Oncology.

A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21).

J. Ahn, M. Ahn, Keunchil Park, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment

J. Ahn, Y. Im, I. Do, 2013, British Journal of Cancer.

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

J. Ahn, M. Ahn, Keunchil Park, 2023, Cancer research and treatment.

Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP

Sheehyun Kim, K. Jang, J. Cheon, 2023, Cancer research and treatment.

A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas

Sung-Bae Kim, M. Ahn, Keun-Wook Lee, 2023, Cancer.

Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced Non-small Cell Lung Cancer.

J. Ahn, M. Ahn, Soohyun Hwang, 2023, Journal of Thoracic Oncology.

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer

Hye Hyeon Eum, Jong-Mu Sun, J. Cho, 2024, bioRxiv.